Latest Production News

Nutritional Growth Solutions reported a slight revenue decline in Q4 FY24 but remains optimistic about growth and profitability in FY25, buoyed by renewed Walmart partnerships and expanding Asian distribution.

Western Gold Resources Limited has secured expanded mining approvals, confirmed strong metallurgical recoveries, and updated its mineral resource estimate at the Gold Duke Project, positioning the company for a transition to production.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Magnis Energy Technologies reports ongoing progress on its Nachu Graphite Project while grappling with Imperium3’s bankruptcy and a prolonged ASX trading suspension.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Adelong Gold Limited's December 2024 quarterly report reveals promising new drill targets near the Adelong Mill and a binding farm-in agreement with Great Divide Mining to accelerate gold production.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Jindalee Lithium Limited reported a $935,000 net cash outflow for the December 2024 quarter, maintaining a cautious but confident stance on securing future funding to support ongoing exploration activities.

Jindalee Lithium’s latest quarterly report confirms a 63-year life for its McDermitt Lithium Project, underpinned by robust financial metrics and a maiden ore reserve that taps just a fraction of its vast resource.

Oldfields Holdings Limited reports a robust second quarter for FY2025, highlighting successful strategic realignment and improved financial performance despite ongoing transition costs.

Larvotto Resources has reported robust progress at its Hillgrove Antimony-Gold Project, highlighted by exceptional drilling results and a successful $30 million capital raise, positioning the company for production by late 2025.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.